Potent LILRB1 D1D2-containing antibodies inhibit RIFIN-mediated immune evasions.

A preprint abstract from biorxiv.org discusses the role of antibodies in inhibiting immune evasions caused by Plasmodium falciparum, the parasite that causes malaria. The study focuses on the interaction between RIFIN, a variant surface antigen of the parasite, and LILRB1, an immunoinhibitory receptor. The researchers propose a strategy for generating antibodies containing LILRB1-D1D2, which effectively block the binding of RIFIN to LILRB1. They also develop a bispecific antibody that enhances natural killer cell-mediated cytotoxicity against RIFIN-expressing cells. This research has the potential to contribute to the development of malaria treatments and vaccines. [Extracted from the article]

Copyright of Zika & Mosquito Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)